Key takeaways
Liraglutide (Saxenda) and tirzepatide (Mounjaro) are both medications used to help manage weight and blood sugar levels, but they have different primary uses and mechanisms of action. Both medications are injected under the skin and are not controlled substances. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in adults and children with a high body mass index (BMI). Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved for Type 2 diabetes management. Saxenda is injected daily, whereas Mounjaro is injected weekly. Both medications are available as a brand-name medication only. Common side effects of both medications include nausea, vomiting, and diarrhea. Both medications carry a risk of thyroid cancer, pancreatitis, and gallbladder problems, and they should not be used if you have a personal or family history of certain thyroid cancers. Mounjaro can also affect birth control effectiveness, so additional precautions may be needed.
